Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rapid Micro Biosystems (RPID) Gains from Investment Securities (2020 - 2025)

Historic Gains from Investment Securities for Rapid Micro Biosystems (RPID) over the last 6 years, with Q3 2025 value amounting to $1000.0.

  • Rapid Micro Biosystems' Gains from Investment Securities fell 9923.08% to $1000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $419000.0, marking a year-over-year increase of 17933.33%. This contributed to the annual value of $150000.0 for FY2024, which is 66.23% down from last year.
  • Rapid Micro Biosystems' Gains from Investment Securities amounted to $1000.0 in Q3 2025, which was down 9923.08% from $427000.0 recorded in Q2 2025.
  • In the past 5 years, Rapid Micro Biosystems' Gains from Investment Securities ranged from a high of $11.4 million in Q1 2021 and a low of -$9000.0 during Q1 2025
  • Its 5-year average for Gains from Investment Securities is $2.6 million, with a median of $131500.0 in 2023.
  • Over the last 5 years, Rapid Micro Biosystems' Gains from Investment Securities had its largest YoY gain of 417000.0% in 2025, and its largest YoY loss of 19000.0% in 2025.
  • Over the past 5 years, Rapid Micro Biosystems' Gains from Investment Securities (Quarter) stood at $8.2 million in 2021, then crashed by 30.48% to $5.7 million in 2022, then tumbled by 97.66% to $133000.0 in 2023, then dropped by 2.26% to $130000.0 in 2024, then plummeted by 99.23% to $1000.0 in 2025.
  • Its Gains from Investment Securities stands at $1000.0 for Q3 2025, versus $427000.0 for Q2 2025 and -$9000.0 for Q1 2025.